肺癌患者血清中PDCD5、Bax含量与肿瘤病灶内病理特征的相关性研究
|
摘要
目的:研究肺癌患者血清中PDCD5、Bax含量与肿瘤病灶内病理特征的相关性。方法:选择在本院接受手术治疗的肺癌患者作为研究的肺癌组,术前取血清标本、术后取肺癌病灶及癌旁病灶;选择同期在华西医院体检的健康者作为对照组,体检时取血清标本;测定血清中PDCD5、Bax的含量以及肺癌病灶、癌旁病灶中PDCD5、Bax含量及增殖基因、侵袭基因的表达量。结果:肺癌组血清中PDCD5、Bax的含量显著低于对照组,肺癌病灶内PDCD5、Bax的含量显著低于癌旁病灶且肺癌患者血清中PDCD5、Bax的含量与肺癌病灶内PDCD5、Bax的含量呈正相关;肺癌病灶中C-myc、RACK1、CatL、MMP2、N-cadherin的mRNA表达量显著高于癌旁病灶且与血清中PDCD5、Bax的含量呈负相关,LAST1、PAQR3、TCF21、E-cadherin、TIMP1、TIMP2的mRNA表达量显著低于癌旁病灶且与血清中PDCD5、Bax的含量呈正相关。结论:肺癌患者血清中PDCD5、Bax含量的降低与肿瘤病灶内癌细胞增殖、侵袭的加剧密切相关。
Objective:To study the correlation of serum PDCD5 and Bax contents with the pathological features of tumor lesions in patients with lung cancer.Methods:Patients with lung cancer who underwent surgical treatment in West China Hospital between June 2014 and March 2017 were selected as the lung cancer group for the study,the serum specimens were collected before surgery,and the lung cancer lesion and adjacent lesion were taken after surgery;the healthy subjects who underwent physical examination in West China Hospital during the same period were selected as the control group,and the serum samples were taken during the physical examination;the contents of PDCD5 and Bax in serum as well as the contents of PDCD5 and Bax,and the expression of proliferation genes and invasion genes in the lung cancer lesion and adjacent lesion were measured.Results:PDCD5 and Bax contents in serum of lung cancer group were significantly lower than those of control group,PDCD5 and Bax contents in lung cancer lesion were significantly lower than those in adjacent lesion,and the PDCD5 and Bax contents in serum of patients with lung cancer were positively correlated with the PDCD5 and Bax contents in lung cancer lesion;C-myc,RACK1,CatL,MMP2 and N-cadherin mRNA expression in lung cancer lesion were significantly higher than those in adjacent lesion and negatively correlated with PDCD5 and Bax contents in serum whereas LAST1,PAQR3,TCF21,E-cadherin,TIMP1 and TIMP2 mRNA expression were significantly lower than those in adjacent lesion and positively correlated with PDCD5 and Bax contents in serum.Conclusion:The decrease of PDCD5 and Bax in serum of patients with lung cancer is closely related to the aggravation of cancer cell proliferation and invasion in tumor lesions.
Objective:To study the correlation of serum PDCD5 and Bax contents with the pathological features of tumor lesions in patients with lung cancer.Methods:Patients with lung cancer who underwent surgical treatment in West China Hospital between June 2014 and March 2017 were selected as the lung cancer group for the study,the serum specimens were collected before surgery,and the lung cancer lesion and adjacent lesion were taken after surgery;the healthy subjects who underwent physical examination in West China Hospital during the same period were selected as the control group,and the serum samples were taken during the physical examination;the contents of PDCD5 and Bax in serum as well as the contents of PDCD5 and Bax,and the expression of proliferation genes and invasion genes in the lung cancer lesion and adjacent lesion were measured.Results:PDCD5 and Bax contents in serum of lung cancer group were significantly lower than those of control group,PDCD5 and Bax contents in lung cancer lesion were significantly lower than those in adjacent lesion,and the PDCD5 and Bax contents in serum of patients with lung cancer were positively correlated with the PDCD5 and Bax contents in lung cancer lesion;C-myc,RACK1,CatL,MMP2 and N-cadherin mRNA expression in lung cancer lesion were significantly higher than those in adjacent lesion and negatively correlated with PDCD5 and Bax contents in serum whereas LAST1,PAQR3,TCF21,E-cadherin,TIMP1 and TIMP2 mRNA expression were significantly lower than those in adjacent lesion and positively correlated with PDCD5 and Bax contents in serum.Conclusion:The decrease of PDCD5 and Bax in serum of patients with lung cancer is closely related to the aggravation of cancer cell proliferation and invasion in tumor lesions.
引文
1 Wang P,Zou J,Wu J,et al.Clinical profiles and trend analysis of newly diagnosed lung cancer in a tertiary care hospital of East China during 2011-2015[J].J Thorac Dis,2017,9(7):1973-1979.
2 Wang D,Wang W,Song CL,et al.The roles of serum PDCD5in circulating CD133positive cells of the patients with gastric cancer[J].Tumour Biol,2016,37(9):11799-11804.
3 Gao L,Ye X,Ma RQ,et al.Low programmed cell death 5expression is a prognostic factor in ovarian cancer[J].Chin Med J,2015,128(8):1084-1090.
4 Russo A,Cardile V,Graziano ACE,et al.Involvement of Bax and Bcl-2in Induction of Apoptosis by Essential Oils of Three Lebanese Salvia Species in Human Prostate Cancer Cells[J].Int J Mol Sci,2018,19(1):E292.
5 Wang W,Song XW,Zhao CH.Roles of programmed cell death protein 5in inflammation and cancer(Review)[J].Int J Oncol,2016,49(5):1801-1806.
6 Xu S,Sui G,Yuan L,et al.Expression of programmed cell death 5 protein inhibits progression of lung carcinoma in vitro and in vivo via the mitochondrial apoptotic pathway[J].Mol Med Rep,2014,10(4):2059-64.
7 Xu L,Wang Z,He SY,et al.Bax-interacting factor-1inhibits cell proliferation and promotes apoptosis in prostate cancer cells[J].Oncol Rep,2016,36(6):3513-3521.
8 Yang J,Ning J,Peng L,et al.Effect of curcumin on Bcl-2and Bax expression in nude mice prostate cancer[J].Int J Clin Exp Pathol,2015,8(8):9272-9278.
9 Barfeld SJ,Urbanucci A,Itkonen HM,et al.c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks[J].EBioMedicine,2017,18:83-93.
10 Minciacchi VR,Spinelli C,Reis-Sobreiro M,et al.MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer[J].Cancer Res,2017,77(9):2306-2317.
11 Shen F,Yan C,Liu M,et al.RACK1promotes prostate cancer cell proliferation,invasion and metastasis[J].Mol Med Rep,2013,8(4):999-1004.
12 Ye XY,Luo QQ,Xu YH,et al.17-AAG suppresses growth and invasion of lung adenocarcinoma cells via regulation of the LATS1/YAP pathway[J].J Cell Mol Med,2015,19(3):651-63.
13 Yeung B,Yu J,Yang X.Roles of the Hippo pathway in lung development and tumorigenesis[J].Int J Cancer,2016,138(3):533-539.
14 Costa VL,Henrique R,Danielsen SA,et al.TCF21and PCDH17methylation:An innovative panel of biomarkers for a simultaneous detection of urological cancers[J].Epigenetics,2011,6(9):1120-1130.
15 Han ML,Zhao YF,Tan CH,et al.Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549cells[J].Acta Pharmacol Sin,2016,37(12):1606-1622.
16 Pouyanfar N,Monabbati A,Sharifi AA,et al.Expression Levels of MMP9and PIWIL2in Prostate Cancer:a Case-Control Study[J].Clin Lab,2016,62(4):651-657.
17 Reis ST,Viana NI,Iscaife A,et al.Loss of TIMP-1immune expression and tumor recurrence in localized prostate cancer[J].Int Braz J Urol,2015,41(6):1088-1095.
18 Palmirotta R,Cives M,Della-Morte D,et al.Sirtuins and Cancer:Role in the Epithelial-Mesenchymal Transition[J].Oxid Med Cell Longev,2016,2016:3031459.
19 Atmaca A,Wirtz RW,Werner D,et al.SNAI2/SLUG and estrogen receptor mRNA expression are inversely correlated and prognostic of patient outcome in metastatic non-small cell lung cancer[J].BMC Cancer,2015,17(15):300.
2 Wang D,Wang W,Song CL,et al.The roles of serum PDCD5in circulating CD133positive cells of the patients with gastric cancer[J].Tumour Biol,2016,37(9):11799-11804.
3 Gao L,Ye X,Ma RQ,et al.Low programmed cell death 5expression is a prognostic factor in ovarian cancer[J].Chin Med J,2015,128(8):1084-1090.
4 Russo A,Cardile V,Graziano ACE,et al.Involvement of Bax and Bcl-2in Induction of Apoptosis by Essential Oils of Three Lebanese Salvia Species in Human Prostate Cancer Cells[J].Int J Mol Sci,2018,19(1):E292.
5 Wang W,Song XW,Zhao CH.Roles of programmed cell death protein 5in inflammation and cancer(Review)[J].Int J Oncol,2016,49(5):1801-1806.
6 Xu S,Sui G,Yuan L,et al.Expression of programmed cell death 5 protein inhibits progression of lung carcinoma in vitro and in vivo via the mitochondrial apoptotic pathway[J].Mol Med Rep,2014,10(4):2059-64.
7 Xu L,Wang Z,He SY,et al.Bax-interacting factor-1inhibits cell proliferation and promotes apoptosis in prostate cancer cells[J].Oncol Rep,2016,36(6):3513-3521.
8 Yang J,Ning J,Peng L,et al.Effect of curcumin on Bcl-2and Bax expression in nude mice prostate cancer[J].Int J Clin Exp Pathol,2015,8(8):9272-9278.
9 Barfeld SJ,Urbanucci A,Itkonen HM,et al.c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks[J].EBioMedicine,2017,18:83-93.
10 Minciacchi VR,Spinelli C,Reis-Sobreiro M,et al.MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer[J].Cancer Res,2017,77(9):2306-2317.
11 Shen F,Yan C,Liu M,et al.RACK1promotes prostate cancer cell proliferation,invasion and metastasis[J].Mol Med Rep,2013,8(4):999-1004.
12 Ye XY,Luo QQ,Xu YH,et al.17-AAG suppresses growth and invasion of lung adenocarcinoma cells via regulation of the LATS1/YAP pathway[J].J Cell Mol Med,2015,19(3):651-63.
13 Yeung B,Yu J,Yang X.Roles of the Hippo pathway in lung development and tumorigenesis[J].Int J Cancer,2016,138(3):533-539.
14 Costa VL,Henrique R,Danielsen SA,et al.TCF21and PCDH17methylation:An innovative panel of biomarkers for a simultaneous detection of urological cancers[J].Epigenetics,2011,6(9):1120-1130.
15 Han ML,Zhao YF,Tan CH,et al.Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549cells[J].Acta Pharmacol Sin,2016,37(12):1606-1622.
16 Pouyanfar N,Monabbati A,Sharifi AA,et al.Expression Levels of MMP9and PIWIL2in Prostate Cancer:a Case-Control Study[J].Clin Lab,2016,62(4):651-657.
17 Reis ST,Viana NI,Iscaife A,et al.Loss of TIMP-1immune expression and tumor recurrence in localized prostate cancer[J].Int Braz J Urol,2015,41(6):1088-1095.
18 Palmirotta R,Cives M,Della-Morte D,et al.Sirtuins and Cancer:Role in the Epithelial-Mesenchymal Transition[J].Oxid Med Cell Longev,2016,2016:3031459.
19 Atmaca A,Wirtz RW,Werner D,et al.SNAI2/SLUG and estrogen receptor mRNA expression are inversely correlated and prognostic of patient outcome in metastatic non-small cell lung cancer[J].BMC Cancer,2015,17(15):300.